Get the Stockscreener App
14.54
3.71%
0.52
Pre-market:
14.11
-0.43
-2.96%
Atrium Therapeutics Inc Stock (RNA) Forecast
The Atrium Therapeutics Inc (RNA) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $16.43, representing a +12.98% increase from the current price of $14.54. The highest analyst price target is $18.75, and the lowest is $14.11.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month RNA Price Target
Average 14.44
(-0.69% Downside)
Is Atrium Therapeutics Inc (RNA) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 27.63 | Buy |
| STOCH(9,6) | 60.26 | Neutral |
| STOCHRSI(14) | 100.00 | Sell |
| MACD(12,26) | -4.4166 | Buy |
| ADX(14) | 73.39 | Sell |
| William %R | -3.0457 | Sell |
| CCI(14) | 142.96 | Buy |
Buy: 3
Sell: 3
Neutral: 1
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
13.66
Buy
|
13.79
Buy
|
| MA20 |
13.37
Buy
|
15.83
Sell
|
| MA50 |
33.96
Sell
|
29.18
Sell
|
| MA100 |
52.97
Sell
|
41.00
Sell
|
| MA200 |
49.63
Sell
|
44.51
Sell
|
Buy: 3
Sell: 7
Neutral: 0
Summary: Sell
According to our latest analysis, RNA could be considered a Strong Sell, with 17 technical analysis indicators signaling 6 Buy signals, 10 signaling Sell signals and 1 Neutral signals. This might not be a good time to consider opening new positions on RNA, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 27.63 indicates that RNA is oversold. This indicates that RNA price has experienced a significant decline over a specified lookback period, potentially leading to a rebound.
- STOCH (Stochastic Oscillator): The STOCH value of 60.26 indicates that RNA is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 100 indicates that RNA is oversold. This suggests that RNA price is at or near the highest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 73.39 suggests an extremely strong trend in the market. Such high values are relatively rare and indicate a very robust directional movement.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 142.96 indicates that RNA is overbought. This means that the price has moved significantly higher than its average, indicating a potential selling opportunity.
Long-term RNA price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Atrium Therapeutics Inc financial reports and earnings history, Atrium Therapeutics Inc (RNA) stock could reach $18.99 by 2030, $11.76 by 2040 and $6.0876 by 2050. See the projected annual prices until 2050 of the Atrium Therapeutics Inc stock below:
- Atrium Therapeutics Inc (RNA) is expected to reach an average price of $7.1556 in 2035, with a high prediction of $9.9122 and a low estimate of $5.6023. This indicates an $-50.79% rise from the last recorded price of $14.54.
- Atrium Therapeutics Inc (RNA) stock is projected to chart a bullish course in 2040, with an average price target of $11.71, representing an $-19.45% surge from its current level. The forecast ranges from a conservative $5.0182 to a sky-high $11.76.
- Our analysts predict Atrium Therapeutics Inc (RNA) to jump -30.54% by 2045, soaring from $8.8526 to an average price of $10.10, potentially reaching $13.02. While $8.8526 is the low estimate, the potential upside is significant.
- Atrium Therapeutics Inc (RNA) stock is expected to climb by 2050, reaching an average of $6.7176, a $-53.80% jump from its current level. However, a wide range of estimates exists, with high and low targets of $6.0876 and $5.7675, respectively, highlighting the market's uncertainty.
Atrium Therapeutics Inc Stock (RNA) Year by Year Forecast
Atrium Therapeutics Inc Stock (RNA) Price Forecast for 2026
The predicted value for Atrium Therapeutics Inc (RNA) in 2026 is set at an average of $16.36. Estimates vary from a peak of $24.40 to a trough of $8.3207, indicating an +12.51% surge from the present price of $14.54.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| May, 2026 | $17.16 | $14.11 | $18.75 | +18.01% |
| June, 2026 | $11.00 | $10.77 | $17.04 | -24.33% |
| July, 2026 | $10.54 | $8.444 | $12.55 | -27.52% |
| August, 2026 | $11.96 | $8.3207 | $13.22 | -17.72% |
| September, 2026 | $13.73 | $11.93 | $16.79 | -5.58% |
| October, 2026 | $19.38 | $12.70 | $21.01 | +33.31% |
| November, 2026 | $18.28 | $15.90 | $20.74 | +25.70% |
| December, 2026 | $11.68 | $11.07 | $18.84 | -19.65% |
Atrium Therapeutics Inc Stock (RNA) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Atrium Therapeutics Inc (RNA) is $14.13, with a high forecast of $23.21 and a low forecast of $5.0393. This indicates an -2.84% decrease from the last price of $14.54.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $12.30 | $10.47 | $14.31 | -15.42% |
| February, 2027 | $9.0917 | $8.3517 | $12.93 | -37.47% |
| March, 2027 | $17.30 | $7.2928 | $20.76 | +18.96% |
| April, 2027 | $21.17 | $15.32 | $21.59 | +45.61% |
| May, 2027 | $20.25 | $19.65 | $23.21 | +39.24% |
| June, 2027 | $17.51 | $16.86 | $22.86 | +20.44% |
| July, 2027 | $13.81 | $10.62 | $18.28 | -5.05% |
| August, 2027 | $8.3105 | $7.8705 | $15.04 | -42.84% |
| September, 2027 | $9.616 | $7.8627 | $10.21 | -33.87% |
| October, 2027 | $8.3304 | $8.1393 | $9.6171 | -42.71% |
| November, 2027 | $6.7849 | $6.3626 | $8.5815 | -53.34% |
| December, 2027 | $5.4704 | $5.0393 | $7.3438 | -62.38% |
Atrium Therapeutics Inc Stock (RNA) Price Forecast for 2028
In 2028, Atrium Therapeutics Inc (RNA) is projected to reach an average price of $15.97, with a high projection of $29.60 and a low estimate of $2.3454. This indicates an +9.87% rise from the last price of $14.54.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $3.8948 | $3.6248 | $5.4915 | -73.21% |
| February, 2028 | $2.3892 | $2.3592 | $4.4261 | -83.57% |
| March, 2028 | $3.7848 | $2.3454 | $4.2037 | -73.97% |
| April, 2028 | $6.1792 | $3.4959 | $6.2192 | -57.50% |
| May, 2028 | $7.6948 | $5.9003 | $9.4236 | -47.08% |
| June, 2028 | $10.89 | $7.4659 | $11.05 | -25.11% |
| July, 2028 | $17.65 | $10.55 | $17.89 | +21.41% |
| August, 2028 | $22.18 | $13.84 | $25.21 | +52.54% |
| September, 2028 | $21.68 | $19.79 | $23.57 | +49.13% |
| October, 2028 | $21.22 | $20.10 | $29.60 | +45.97% |
| November, 2028 | $18.35 | $17.68 | $23.61 | +26.17% |
| December, 2028 | $25.07 | $18.02 | $27.15 | +72.45% |
Atrium Therapeutics Inc Stock (RNA) Price Forecast for 2029
The 2029 price forecast for Atrium Therapeutics Inc Stock (RNA) is $22.96 on average, with a high prediction of $32.10 and a low estimate of $13.83. This represents an +57.92% increase from the previous price of $14.54.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $28.95 | $22.51 | $32.10 | +99.07% |
| February, 2029 | $22.31 | $20.89 | $30.68 | +53.47% |
| March, 2029 | $22.63 | $18.45 | $25.25 | +55.66% |
| April, 2029 | $24.51 | $22.46 | $27.10 | +68.58% |
| May, 2029 | $20.10 | $19.68 | $30.69 | +38.26% |
| June, 2029 | $17.56 | $17.01 | $23.32 | +20.78% |
| July, 2029 | $18.82 | $16.39 | $22.37 | +29.44% |
| August, 2029 | $16.51 | $14.52 | $22.84 | +13.56% |
| September, 2029 | $17.19 | $13.83 | $20.49 | +18.23% |
| October, 2029 | $18.46 | $14.22 | $20.60 | +26.97% |
| November, 2029 | $23.99 | $16.21 | $24.09 | +65.00% |
| December, 2029 | $17.49 | $15.88 | $24.32 | +20.29% |
Atrium Therapeutics Inc Stock (RNA) Price Forecast for 2030
Atrium Therapeutics Inc Stock (RNA) is expected to reach an average price of $14.95 in 2030, with a high forecast of $24.03 and a low forecast of $5.868. This signifies an +2.83% surge from the last price of $14.54.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $14.90 | $12.33 | $18.99 | +2.48% |
| February, 2030 | $17.32 | $12.86 | $19.31 | +19.12% |
| March, 2030 | $18.03 | $16.56 | $19.74 | +23.99% |
| April, 2030 | $17.25 | $15.05 | $19.21 | +18.62% |
| May, 2030 | $17.12 | $15.68 | $24.03 | +17.73% |
| June, 2030 | $20.41 | $15.42 | $21.79 | +40.35% |
| July, 2030 | $10.05 | $8.1982 | $20.73 | -30.89% |
| August, 2030 | $9.747 | $9.637 | $12.50 | -32.96% |
| September, 2030 | $12.36 | $9.4792 | $13.29 | -15.02% |
| October, 2030 | $14.58 | $10.37 | $16.17 | +0.25% |
| November, 2030 | $8.4258 | $8.1958 | $14.46 | -42.05% |
| December, 2030 | $8.7847 | $5.868 | $9.9703 | -39.58% |
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):